These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 15196569

  • 1. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO, Dias WO, Schenkman RP, Raw I, Tanizaki MM.
    FEMS Immunol Med Microbiol; 2004 Jul 01; 41(3):205-10. PubMed ID: 15196569
    [Abstract] [Full Text] [Related]

  • 2. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G, Aase A, Caugant DA, Høiby EA, Fritzsønn E, Tangen T, Kristiansen P, Heggelund U, Rosenqvist E.
    Vaccine; 2005 May 31; 23(29):3762-74. PubMed ID: 15893613
    [Abstract] [Full Text] [Related]

  • 3. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G, Arnemo M, Næss LM, Fjeldheim ÅK, Nome L, Bolstad K, Aase A, Mandiarote A, González H, González D, García L, Cardoso D, Norheim G, Rosenqvist E.
    Vaccine; 2013 Dec 09; 31(51):6097-106. PubMed ID: 24120679
    [Abstract] [Full Text] [Related]

  • 4. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL, van den Dobbelsteen GP, de Groot R.
    Curr Opin Mol Ther; 2003 Feb 09; 5(1):33-8. PubMed ID: 12669468
    [Abstract] [Full Text] [Related]

  • 5. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates.
    Carmenate T, Canaán L, Alvarez A, Delgado M, González S, Menéndez T, Rodés L, Guillén G.
    FEMS Immunol Med Microbiol; 2004 Apr 09; 40(3):193-9. PubMed ID: 15039094
    [Abstract] [Full Text] [Related]

  • 6. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E.
    Vaccine; 2009 Jun 24; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [Abstract] [Full Text] [Related]

  • 7. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
    Toropainen M, Saarinen L, Wedege E, Bolstad K, Mäkelä PH, Käyhty H.
    Vaccine; 2005 Sep 23; 23(40):4821-33. PubMed ID: 15970361
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H, Feavers IM.
    Expert Rev Vaccines; 2011 Mar 23; 10(3):323-34. PubMed ID: 21434800
    [Abstract] [Full Text] [Related]

  • 9. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D.
    Vaccine; 2007 Sep 28; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract] [Full Text] [Related]

  • 10. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D.
    Expert Rev Vaccines; 2009 May 28; 8(5):529-42. PubMed ID: 19397410
    [Abstract] [Full Text] [Related]

  • 11. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.
    Int J Infect Dis; 2008 May 28; 12(3):278-88. PubMed ID: 17981067
    [Abstract] [Full Text] [Related]

  • 12. Quadrivalent meningococcal conjugate vaccines.
    Pace D, Pollard AJ, Messonier NE.
    Vaccine; 2009 Jun 24; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [Abstract] [Full Text] [Related]

  • 13. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M, Yero D, Niebla O, González S, Climent Y, Pérez Y, Cobas K, Caballero E, García D, Pajón R.
    Vaccine; 2007 Dec 05; 25(50):8420-31. PubMed ID: 17996338
    [Abstract] [Full Text] [Related]

  • 14. Recombinant outer membrane secretin PilQ(406-770) as a vaccine candidate for serogroup B Neisseria meningitidis.
    Haghi F, Peerayeh SN, Siadat SD, Zeighami H.
    Vaccine; 2012 Feb 21; 30(9):1710-4. PubMed ID: 22234267
    [Abstract] [Full Text] [Related]

  • 15. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M, Fantoni S.
    Minerva Med; 2007 Oct 21; 98(5):575-89. PubMed ID: 18043565
    [Abstract] [Full Text] [Related]

  • 16. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R, Levy C.
    Arch Pediatr; 2012 Sep 21; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [Abstract] [Full Text] [Related]

  • 17. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E, da Silveira IF, Larangeira AP, Pereira S, Fernandes SA, Rabinovitch L, Frasch CE, Castro-Faria-Neto HC, Bozza PT.
    Vaccine; 2004 Jun 30; 22(20):2617-25. PubMed ID: 15193387
    [Abstract] [Full Text] [Related]

  • 18. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J, Taylor S, Aase A, Horton R, Heyderman R, Southern J, Andrews N, Barchha R, Harrison E, Lowe A, Boxer E, Heaton C, Balmer P, Kaczmarski E, Oster P, Gorringe A, Borrow R, Miller E.
    Infect Immun; 2006 Aug 30; 74(8):4557-65. PubMed ID: 16861642
    [Abstract] [Full Text] [Related]

  • 19. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P.
    Vaccine; 2007 Apr 20; 25(16):3080-4. PubMed ID: 17287053
    [Abstract] [Full Text] [Related]

  • 20. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Borrow R, Balmer P, Miller E.
    Vaccine; 2005 Mar 18; 23(17-18):2222-7. PubMed ID: 15755600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.